FOLH1 and prostate cancer: It has been reported that significant tumor regression and prolonged survival using high-specific-activity 177Lu-PSMA-617 are seen in a syngeneic murine prostate cancer model, with superior efficacy observed at higher specific activities and no subacute hematologic toxicity [49].